42. 結節性多発動脈炎 Polyarteritis nodosa Clinical trials / Disease details
臨床試験数 : 14 / 薬物数 : 27 - (DrugBank : 16) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 104
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-003964-30-GB (EUCTR) | 22/10/2020 | 31/07/2020 | Biologics in refractory vasculitis (BIOVAS): A pragmatic, randomised, double-blind, placebo-controlled, modified-crossover trial of biologic therapy for refractory vasculitis in adults and children. | Biologics in refractory vasculitis (BIOVAS): A pragmatic, randomised, double-blind, placebo-controlled, modified-crossover trial of biologic therapy for refractory primary non-ANCA associated vasculitis in adults and children - Biologics in refractory vasculitis (BIOVAS) | Non-ANCA associated vasculitides: 1.Giant cell arteritis (GCA)2.Takayasu’s arteritis (TA)3.Polyarteritis nodosa (PAN) or cutaneous polyarteritis unrelated to hepatitis B (CPAN)4.Relapsing polychondritis (RP)5.IgA vasculitis (IgAV)6.Cogan’s syndrome7.Non-infective cryoglobulinaemia8.Primary angiitis of central nervous system (PACNS) MedDRA version: 21.1;Level: PT;Classification code 10047115;Term: Vasculitis;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Infliximab Product Code: N/A INN or Proposed INN: Infliximab Trade Name: Rituximab Product Name: Rituximab INN or Proposed INN: Rituximab Trade Name: Tocilizumab Product Name: Tocilizumab Product Code: N/A INN or Proposed INN: Tocilizumab | Cambridge University Hospitals NHS Foundation Trust | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 140 | Phase 2 | United Kingdom | ||
| 2 | NCT03482479 (ClinicalTrials.gov) | February 4, 2019 | 22/3/2018 | Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis | Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis | Eosinophilic Granulomatosis With Polyangiitis (EGPA);Churg-Strauss Syndrome (CSS);Giant Cell Arteritis;Granulomatosis With Polyangiitis;Microscopic Polyangiitis;Polyarteritis Nodosa;Takayasu Arteritis | Drug: Naltrexone Hydrochloride;Other: Placebo Comparator | University of Pennsylvania | NULL | Recruiting | 18 Years | N/A | All | 36 | Phase 2 | United States |
| 3 | NCT02939573 (ClinicalTrials.gov) | January 1, 2017 | 18/10/2016 | A Randomized Multicenter Study for Isolated Skin Vasculitis | A Randomized Multicenter Study for Isolated Skin Vasculitis | Primary Cutaneous Vasculitis;Cutaneous Polyarteritis Nodosa;IgA Vasculitis;Henoch-Schönlein Purpura | Drug: Colchicine;Drug: Dapsone;Drug: Azathioprine | University of Pennsylvania | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);National Center for Advancing Translational Science (NCATS);Office of Rare Diseases (ORD) | Recruiting | 18 Years | N/A | All | 90 | Phase 2 | United States;Canada;Japan |
| 4 | EUCTR2013-004668-71-ES (EUCTR) | 13/10/2016 | 05/08/2016 | A study of treatment for polyarteritis nodosa in children | An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN | Childhood systemic polyarteritis nodosa (PAN) MedDRA version: 19.0;Level: LLT;Classification code 10036026;Term: Polyarteritis nodosa of childhood;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept (Mycophenolate Mofetil) Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: Cyclophosphamide Product Name: Cyclophosphamide INN or Proposed INN: CYCLOPHOSPHAMIDE | University College London | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Belgium;Poland;Croatia;Germany;Netherlands;Sweden | ||
| 5 | EUCTR2013-004668-71-IT (EUCTR) | 01/08/2016 | 14/07/2015 | An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN | An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN | Childhood systemic polyarteritis nodosa (PAN) MedDRA version: 19.0;Level: LLT;Classification code 10036026;Term: Polyarteritis nodosa of childhood;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept (Mycophenolate Mofetil) Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: Cyclophosphamide Product Name: Cyclophosphamide | University College London | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Belgium;Poland;Croatia;Germany;Netherlands;Sweden | ||
| 6 | EUCTR2013-004668-71-GB (EUCTR) | 25/09/2014 | 25/09/2014 | A study of treatment for polyarteritis nodosa in children | An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN | Childhood systemic polyarteritis nodosa (PAN) MedDRA version: 17.0;Level: LLT;Classification code 10036026;Term: Polyarteritis nodosa of childhood;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept (Mycophenolate Mofetil) Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: Cyclophosphamide Product Name: Cyclophosphamide | University College London | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | Croatia;Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Belgium;Poland;Germany;Netherlands;Sweden | ||
| 7 | NCT00751517 (ClinicalTrials.gov) | September 2008 | 11/9/2008 | Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides | Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides. A Randomized Controlled Trial. | Wegener's Granulomatosis;Churg-Strauss Syndrome;Microscopic Polyangiitis;Polyarteritis Nodosa | Drug: Methotrexate;Drug: Cyclophosphamide | University of Parma | NULL | Active, not recruiting | 18 Years | 80 Years | Both | Phase 2 | Italy | |
| 8 | NCT00647166 (ClinicalTrials.gov) | May 2008 | 26/3/2008 | Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) | Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Without Poor Prognosis Factors | MPA;PAN or EGPA With FFS=0;At Diagnosis or Within the First 15 Days Following Initiation of Corticosteroids | Drug: corticosteroid and azathioprine;Drug: corticosteroid and placebo | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 18 Years | N/A | Both | 114 | Phase 3 | France |
| 9 | NCT00307671 (ClinicalTrials.gov) | July 2005 | 27/3/2006 | Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years | Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without Immunosuppressants | Vasculitis;Wegener's Granulomatosis;Microscopic Polyangiitis;Churg-Strauss Syndrome;Polyarteritis Nodosa | Drug: prednisone, methylprednisolone,cyclophosphamides;Drug: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Drug: Mycophenolate mofetil,methotrexate | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 65 Years | N/A | Both | 108 | Phase 4 | France |
| 10 | NCT00006055 (ClinicalTrials.gov) | March 2000 | 5/7/2000 | Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases | Purpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu Arteritis | Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell Transplantation | Fairview University Medical Center | NULL | Active, not recruiting | 1 Year | 55 Years | Both | 10 | N/A | United States | |
| 11 | NCT00400075 (ClinicalTrials.gov) | July 1996 | 14/11/2006 | CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors | CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors a Prospective Randomized Study in 125 Patients | Polyarteritis Nodosa;Microscopic Polyangiitis | Drug: azathioprine;Drug: cyclophosphamide | Hospices Civils de Lyon | NULL | Active, not recruiting | 15 Years | 90 Years | Both | 124 | Phase 4 | Switzerland |
| 12 | NCT00001457 (ClinicalTrials.gov) | September 1995 | 3/11/1999 | Lamivudine for Chronic Hepatitis B | Lamivudine for Chronic Hepatitis B | Chronic Hepatitis B;Chronic Hepatitis D;Glomerulonephritis;Polyarteritis Nodosa | Drug: Lamivudine | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NULL | Completed | N/A | N/A | Both | 60 | Phase 2 | United States |
| 13 | EUCTR2013-004668-71-BE (EUCTR) | 12/04/2017 | A study of treatment for polyarteritis nodosa in children | An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN | Childhood systemic polyarteritis nodosa (PAN) MedDRA version: 19.1;Level: LLT;Classification code 10036026;Term: Polyarteritis nodosa of childhood;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept (Mycophenolate Mofetil) Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: Cyclophosphamide Product Name: Cyclophosphamide INN or Proposed INN: CYCLOPHOSPHAMIDE INN or Proposed INN: CYCLOPHOSPHAMIDE | University College London | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Belgium;Poland;Croatia;Germany;Netherlands;Sweden | |||
| 14 | EUCTR2013-004668-71-PT (EUCTR) | 16/02/2016 | A study of treatment for polyarteritis nodosa in children | An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN | Childhood systemic polyarteritis nodosa (PAN) MedDRA version: 18.1;Level: LLT;Classification code 10036026;Term: Polyarteritis nodosa of childhood;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: CellCept (Mycophenolate Mofetil) Product Name: CellCept (Mycophenolate Mofetil) INN or Proposed INN: Mycophenolate mofetil Trade Name: Cyclophosphamide Product Name: Cyclophosphamide INN or Proposed INN: CYCLOPHOSPHAMIDE | University College London | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | Sweden;Netherlands;Germany;Croatia;Poland;Belgium;Czech Republic;Italy;United Kingdom;Turkey;Spain;Greece;Slovenia;Portugal |